Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation. 2015

Katsutsugu Umeda, and Souichi Adachi, and Shiro Tanaka, and Atsushi Ogawa, and Naoki Hatakeyama, and Kazuko Kudo, and Naoki Sakata, and Shunji Igarashi, and Kumi Ohshima, and Nobuyuki Hyakuna, and Motoaki Chin, and Hiroaki Goto, and Yoshiyuki Takahashi, and Eiichi Azuma, and Katsuyoshi Koh, and Akihisa Sawada, and Koji Kato, and Masami Inoue, and Yoshiko Atsuta, and Akiyoshi Takami, and Makoto Murata, and
Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Cyclosporine A (CsA) is used widely for graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation (HSCT); however, the optimal schedule of its administration has not been established. Although comparative studies of adult patients undergoing HSCT have demonstrated enhanced efficacy and safety of twice-daily infusion (TD) compared with continuous infusion (CIF) of CsA, to our knowledge, similar studies have not yet been performed in pediatric groups. A self-administered questionnaire was used to retrospectively compare the clinical outcome and incidence of CsA-associated adverse events of 70 pediatric acute myelogenous leukemia patients who were receiving CsA by TD (n = 36) or CIF (n = 34) as GVHD prophylaxis for their first allogeneic HSCT. The cumulative incidences of grade II-IV acute GVHD and chronic GVHD, as well as the overall survival and event-free survival rates, did not differ significantly between the TD and CIF groups; however, the incidence of severe hypertension was significantly higher in the CIF group than the TD group. The analysis presented here indicates that TD and CIF administration of CsA have similar prophylactic effect on pediatric GVHD and suggest that TD is associated with a lower rate of toxicity than CIF in pediatric patients undergoing HSCT. Pediatr Blood Cancer 2015;62:291-298. © 2014 Wiley Periodicals, Inc.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Katsutsugu Umeda, and Souichi Adachi, and Shiro Tanaka, and Atsushi Ogawa, and Naoki Hatakeyama, and Kazuko Kudo, and Naoki Sakata, and Shunji Igarashi, and Kumi Ohshima, and Nobuyuki Hyakuna, and Motoaki Chin, and Hiroaki Goto, and Yoshiyuki Takahashi, and Eiichi Azuma, and Katsuyoshi Koh, and Akihisa Sawada, and Koji Kato, and Masami Inoue, and Yoshiko Atsuta, and Akiyoshi Takami, and Makoto Murata, and
February 2020, Transplantation,
Katsutsugu Umeda, and Souichi Adachi, and Shiro Tanaka, and Atsushi Ogawa, and Naoki Hatakeyama, and Kazuko Kudo, and Naoki Sakata, and Shunji Igarashi, and Kumi Ohshima, and Nobuyuki Hyakuna, and Motoaki Chin, and Hiroaki Goto, and Yoshiyuki Takahashi, and Eiichi Azuma, and Katsuyoshi Koh, and Akihisa Sawada, and Koji Kato, and Masami Inoue, and Yoshiko Atsuta, and Akiyoshi Takami, and Makoto Murata, and
December 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Katsutsugu Umeda, and Souichi Adachi, and Shiro Tanaka, and Atsushi Ogawa, and Naoki Hatakeyama, and Kazuko Kudo, and Naoki Sakata, and Shunji Igarashi, and Kumi Ohshima, and Nobuyuki Hyakuna, and Motoaki Chin, and Hiroaki Goto, and Yoshiyuki Takahashi, and Eiichi Azuma, and Katsuyoshi Koh, and Akihisa Sawada, and Koji Kato, and Masami Inoue, and Yoshiko Atsuta, and Akiyoshi Takami, and Makoto Murata, and
July 2015, Hematology (Amsterdam, Netherlands),
Katsutsugu Umeda, and Souichi Adachi, and Shiro Tanaka, and Atsushi Ogawa, and Naoki Hatakeyama, and Kazuko Kudo, and Naoki Sakata, and Shunji Igarashi, and Kumi Ohshima, and Nobuyuki Hyakuna, and Motoaki Chin, and Hiroaki Goto, and Yoshiyuki Takahashi, and Eiichi Azuma, and Katsuyoshi Koh, and Akihisa Sawada, and Koji Kato, and Masami Inoue, and Yoshiko Atsuta, and Akiyoshi Takami, and Makoto Murata, and
May 2023, Hematology/oncology and stem cell therapy,
Katsutsugu Umeda, and Souichi Adachi, and Shiro Tanaka, and Atsushi Ogawa, and Naoki Hatakeyama, and Kazuko Kudo, and Naoki Sakata, and Shunji Igarashi, and Kumi Ohshima, and Nobuyuki Hyakuna, and Motoaki Chin, and Hiroaki Goto, and Yoshiyuki Takahashi, and Eiichi Azuma, and Katsuyoshi Koh, and Akihisa Sawada, and Koji Kato, and Masami Inoue, and Yoshiko Atsuta, and Akiyoshi Takami, and Makoto Murata, and
January 2024, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Katsutsugu Umeda, and Souichi Adachi, and Shiro Tanaka, and Atsushi Ogawa, and Naoki Hatakeyama, and Kazuko Kudo, and Naoki Sakata, and Shunji Igarashi, and Kumi Ohshima, and Nobuyuki Hyakuna, and Motoaki Chin, and Hiroaki Goto, and Yoshiyuki Takahashi, and Eiichi Azuma, and Katsuyoshi Koh, and Akihisa Sawada, and Koji Kato, and Masami Inoue, and Yoshiko Atsuta, and Akiyoshi Takami, and Makoto Murata, and
September 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
Katsutsugu Umeda, and Souichi Adachi, and Shiro Tanaka, and Atsushi Ogawa, and Naoki Hatakeyama, and Kazuko Kudo, and Naoki Sakata, and Shunji Igarashi, and Kumi Ohshima, and Nobuyuki Hyakuna, and Motoaki Chin, and Hiroaki Goto, and Yoshiyuki Takahashi, and Eiichi Azuma, and Katsuyoshi Koh, and Akihisa Sawada, and Koji Kato, and Masami Inoue, and Yoshiko Atsuta, and Akiyoshi Takami, and Makoto Murata, and
February 1999, Transplantation,
Katsutsugu Umeda, and Souichi Adachi, and Shiro Tanaka, and Atsushi Ogawa, and Naoki Hatakeyama, and Kazuko Kudo, and Naoki Sakata, and Shunji Igarashi, and Kumi Ohshima, and Nobuyuki Hyakuna, and Motoaki Chin, and Hiroaki Goto, and Yoshiyuki Takahashi, and Eiichi Azuma, and Katsuyoshi Koh, and Akihisa Sawada, and Koji Kato, and Masami Inoue, and Yoshiko Atsuta, and Akiyoshi Takami, and Makoto Murata, and
January 2011, Dermatologic therapy,
Katsutsugu Umeda, and Souichi Adachi, and Shiro Tanaka, and Atsushi Ogawa, and Naoki Hatakeyama, and Kazuko Kudo, and Naoki Sakata, and Shunji Igarashi, and Kumi Ohshima, and Nobuyuki Hyakuna, and Motoaki Chin, and Hiroaki Goto, and Yoshiyuki Takahashi, and Eiichi Azuma, and Katsuyoshi Koh, and Akihisa Sawada, and Koji Kato, and Masami Inoue, and Yoshiko Atsuta, and Akiyoshi Takami, and Makoto Murata, and
November 2016, Haematologica,
Katsutsugu Umeda, and Souichi Adachi, and Shiro Tanaka, and Atsushi Ogawa, and Naoki Hatakeyama, and Kazuko Kudo, and Naoki Sakata, and Shunji Igarashi, and Kumi Ohshima, and Nobuyuki Hyakuna, and Motoaki Chin, and Hiroaki Goto, and Yoshiyuki Takahashi, and Eiichi Azuma, and Katsuyoshi Koh, and Akihisa Sawada, and Koji Kato, and Masami Inoue, and Yoshiko Atsuta, and Akiyoshi Takami, and Makoto Murata, and
September 2011, Blood,
Copied contents to your clipboard!